查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611546

放射性皮膚炎市場規模、佔有率、趨勢分析報告：依產品、通路、地區、細分市場預測，2025-2030

Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Dressings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

放射性皮膚炎市場成長和趨勢

根據Grand View Research, Inc.的最新報告，到2030年，全球放射性皮膚炎市場規模預計將達到5.571億美元，預計2025年至2030年該市場將以4.0%的複合年成長率成長。

全球癌症發生率上升是推動市場成長的關鍵因素。隨著癌症發生率的增加，越來越多的患者接受放射治療作為治療計劃的一部分。 2024 年2 月，世界衛生組織估計，大約20% 的人會在一生中的某個階段被診斷出患有癌症，大約九分之一的男性和十二分之一的女性將受到癌症的影響，因此對癌症的需求不斷成長。這種情況的特徵是由於輻射暴露引起的皮膚發炎和損傷，需要專門的治療，重點是緩解症狀和促進癒合。因此，製藥和醫療設備公司正在優先開發創新治療方法和產品來解決放射性皮膚炎。

在癌症治療期間提高對患者照護的認知和重視對於改善治療結果起著重要作用。醫療保健提供者越來越意識到需要解決與放射治療相關的副作用，例如放射性皮膚炎。 《生物工程與轉化醫學》2024 年 5 月的一篇評論強調了自 20 世紀 80 年代末期以來水凝膠在藥物傳輸、化妝品和組織再生方面的臨床應用。聚合物化學和製造領域的最新進展已經產生了 100 多種由天然、合成或複合材料製成的經 FDA 和 EMA核准的水凝膠產品。這些產品用於多種應用，包括組織再生、臉部矯正、傷口覆蓋和藥物輸送，注射和非注射形式均用於臨床測試。

放射性皮膚炎市場報告亮點

  • 到 2024 年，局部產品細分市場佔據主導地位，市場佔有率為 71.7%，這主要是由於易於獲得、更加方便以及相對於口服替代品的優勢。這些產品預計將顯著成長，因為它們有多種劑型，包括乳膏、凝膠和軟膏，可根據患者需求量身定做。
  • 在分銷管道方面，由於藥局數量的增加，零售藥局細分市場將在2024年佔據39.4%的較大佔有率。零售藥局佔醫院處方的很大一部分。
  • 歐洲憑藉其先進的醫療基礎設施、較高的護膚護理治療意識以及大量接受放射治療的患者，以34.0%的市場佔有率主導全球市場。
  • 由於重大研發舉措創造了有希望的成長機會，北美佔據了第二大市場佔有率。該地區的先進治療產品是促進放射性皮膚炎行業成長的關鍵因素。
  • 競爭的特點是主要企業實施產品發布、分銷聯盟和策略夥伴關係關係等策略，以大幅擴大市場佔有率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章放射性皮膚炎市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 放射性皮膚炎市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章放射性皮膚炎市場：依產品估計和趨勢分析

  • 全球放射性皮膚炎市場：產品儀表板
  • 全球放射性皮膚炎市場：產品變化分析
  • 2018-2030年全球放射性皮膚炎市場規模、預測與趨勢分析
  • 局部的
    • 皮質類固醇
    • 親水霜
    • 抗生素
    • 其他
  • 敷料
    • 水凝膠和親水膠體敷料
    • 無防刺膜
    • 用蜂蜜浸濕的紗布
    • 矽膠塗層敷料
    • 其他

第5章放射性皮膚炎市場：依通路估算與趨勢分析

  • 全球放射性皮膚炎市場：分銷通路儀表板
  • 全球放射性皮膚炎市場：分銷通路波動分析
  • 2018-2030年全球放射性皮膚炎市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章放射性皮膚炎市場：按國家、產品和分銷管道分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要製造商的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 2024年主要企業市場佔有率分析
  • 公司簡介
    • Stratpharma AG
    • Smith &Nephew
    • Molnlycke Health Care AB
    • Derma Sciences Inc.
    • ConvaTec Inc.
    • BMG Pharma SRL
    • Acelity
    • 3M
    • Alliqua BioMedical
Product Code: GVR-1-68038-857-2

Radiodermatitis Market Growth & Trends:

The global radiodermatitis market size is expected to reach USD 557.1 million by 2030, and market is projected to grow at a CAGR of 4.0% from 2025 to 2030, according to a new report by Grand View Research, Inc.. The rising global incidence of cancer is a key factor driving the market growth. As cancer rates increase, more patients are receiving radiation therapy as part of their treatment plans. In February 2024, the WHO reported that around 20% of individuals are expected to be diagnosed with cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness, resulting in a growing need for effective solutions to manage side effects like radiodermatitis. This condition, marked by skin irritation and damage from radiation exposure, calls for specialized treatments focused on alleviating symptoms and promoting healing. Consequently, pharmaceutical and medical device companies prioritize developing innovative therapies and products to address the radiodermatitis industry.

The growing awareness and emphasis on patient care during cancer treatment play a significant role in improving outcomes. Healthcare providers are increasingly acknowledging the need to address side effects related to radiation therapy, such as radiodermatitis. The May 2024 review in Bioengineering & Translational Medicine highlighted the clinical use of hydrogels since the late 1980s across drug delivery, cosmetics, and tissue regeneration. Recent advancements in polymer chemistry and fabrication have resulted in over 100 FDA and EMA-approved hydrogel products derived from natural, synthetic, or combined materials. These products serve various purposes, including tissue regeneration, facial correction, wound dressing, and drug delivery, and include both injectable and non-injectable options in clinical trials.

Radiodermatitis Market Report Highlights:

  • The topical products segment dominated in 2024 with a market share of 71.7%, primarily due to their easy accessibility, enhanced convenience, and advantages over oral alternatives. These products are expected to experience significant growth thanks to their diverse formulations, including creams, gels, and ointments tailored to meet patient needs.
  • In terms of distribution channel, the retail pharmacies segment accounted for a substantial share of 39.4% in 2024 owing to the rising number of pharmacies. Retail pharmacies capture a large percentage of prescriptions written in the hospital.
  • Europe dominated the market globally with a market share of 34.0% due to advanced healthcare infrastructure, high awareness of skin care treatments, and a large patient population undergoing radiation therapy.
  • North America accounted for the second-largest market share due to significant R&D initiatives that have created promising growth opportunities. Advanced therapeutic products in the region are a key factor contributing to its growth in the radiodermatitis industry.
  • The competition features key players implementing strategies like product launches, distribution agreements, and strategic partnerships, which have greatly expanded their market share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution Channel
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Distribution Channel outlook
  • 2.3. Competitive Insights

Chapter 3. Radiodermatitis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of cancer
      • 3.2.1.2. Advancements in dermatological treatments
      • 3.2.1.3. Growing awareness
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Limited availability of specialized products
  • 3.3. Radiodermatitis Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Radiodermatitis Market: Product Estimates & Trend Analysis

  • 4.1. Global Radiodermatitis Market: Product Dashboard
  • 4.2. Global Radiodermatitis Market: Product Movement Analysis
  • 4.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 4.4. Topical
    • 4.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Corticosteroids
      • 4.4.2.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Hydrophilic Creams
      • 4.4.3.1. Hydrophilic creams market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Antibiotics
      • 4.4.4.1. Antibiotics market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Others
      • 4.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.5. Dressings
    • 4.5.1. Dressings market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.2. Hydrogel & Hydrocolloid Dressing
      • 4.5.2.1. Hydrogel & hydrocolloid dressing market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.3. No Sting Barrier Films
      • 4.5.3.1. No sting barrier films market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.4. Honey Impregnated Gauze
      • 4.5.4.1. Honey impregnated gauze market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.5. Silicone Coated Dressings
      • 4.5.5.1. Silicone coated dressings market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.5.6. Others
      • 4.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Global Radiodermatitis Market: Distribution Channel Dashboard
  • 5.2. Global Radiodermatitis Market: Distribution Channel Movement Analysis
  • 5.3. Global Radiodermatitis Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 5.4. Hospital pharmacies
    • 5.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.5. Retail pharmacies
    • 5.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.6. Online pharmacies
    • 5.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Radiodermatitis Market: Regional Estimates & Trend Analysis by Country, Product and Distribution Channel

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Stratpharma AG
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Smith & Nephew
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Molnlycke Health Care AB
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Derma Sciences Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. ConvaTec Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. BMG Pharma S.R.L.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Acelity
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. 3M
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Alliqua BioMedical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 Canada radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Mexico radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 10 Mexico radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Europe radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 13 Europe radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14 Germany radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 15 Germany radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 UK radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 17 UK radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 France radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 19 France radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Italy radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 21 Italy radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 Spain radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 23 Spain radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Denmark radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 25 Denmark radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Sweden radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 27 Sweden radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 29 Norway radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 31 Aisa Pacific radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 China radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 34 China radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Japan radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 36 Japan radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 India radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 38 India radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 South Korea radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 40 South Korea radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Australia radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 42 Australia radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Thailand radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 44 Thailand radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Latin America radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 46 Latin America radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 47 Latin America radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Brazil radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 49 Brazil radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Argentina radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 51 Argentina radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 MEA radiodermatitis market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 54 MEA radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 South Africa radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 56 South Africa radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 UAE radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 60 UAE radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Kuwait radiodermatitis market, by product, 2018 - 2030 (USD Million)
  • Table 62 Kuwait radiodermatitis market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Radiodermatitis market: market outlook
  • Fig. 14 Radiodermatitis competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Radiodermatitis market driver impact
  • Fig. 18 Radiodermatitis market restraint impact
  • Fig. 19 Radiodermatitis market: Type movement analysis
  • Fig. 20 Radiodermatitis market: Type outlook and key takeaways
  • Fig. 21 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Hydrophilic creams market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Hydrogel & hydrocolloid dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 No sting barrier films market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Honey impregnated gauze market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Silicone coated dressings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Radiodermatitis market: Distribution channel movement analysis
  • Fig. 33 Radiodermatitis market: Distribution channel outlook and key takeaways
  • Fig. 34 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 North America, by country
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico key country dynamics
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 UK key country dynamics
  • Fig. 47 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Italy key country dynamics
  • Fig. 53 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Spain key country dynamics
  • Fig. 55 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark key country dynamics
  • Fig. 57 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden key country dynamics
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Norway key country dynamics
  • Fig. 61 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 China key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Japan key country dynamics
  • Fig. 66 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand key country dynamics
  • Fig. 70 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Korea key country dynamics
  • Fig. 72 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Brazil key country dynamics
  • Fig. 77 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Argentina key country dynamics
  • Fig. 79 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 South Africa key country dynamics
  • Fig. 82 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 UAE key country dynamics
  • Fig. 86 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Kuwait key country dynamics
  • Fig. 88 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Market share of key market players - radiodermatitis market